Related references
Note: Only part of the references are listed.Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab
Christopher G. England et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Synthesis of 5-[18F]Fluoro-α-methyl Tryptophan: New Trp Based PET Agents
Benjamin C. Giglio et al.
THERANOSTICS (2017)
Regulation of PD-L1: a novel role of pro-survival signalling in cancer
J. Chen et al.
ANNALS OF ONCOLOGY (2016)
18F-FDG PET/CT Reveals Disease Remission in a Patient With Ipilimumab-Refractory Advanced Melanoma Treated With Pembrolizumab
Christos Sachpekidis et al.
CLINICAL NUCLEAR MEDICINE (2016)
High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma
Yih-Leong Chang et al.
EUROPEAN JOURNAL OF CANCER (2016)
Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery
Egesta Lopci et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma
Melanie Ruf et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer
Mitsunori Higuchi et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2016)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysis
Hyung-Jun Im et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation
Muhammad Zaeem Noman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer
Kyoichi Kaira et al.
LUNG CANCER (2014)
Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy
Seung Hwan Moon et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Biologic Correlation of 2-[18F]-Fluoro-2-Deoxy-D-Glucose Uptake on Positron Emission Tomography in Thymic Epithelial Tumors
Kyoichi Kaira et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Richard L. Wahl et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer
Noriaki Sunaga et al.
LUNG CANCER (2008)
Fluorine-18-α-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer:: A clinicopathologic study
Kyoichi Kaira et al.
CLINICAL CANCER RESEARCH (2007)
Diagnostic usefulness of fluorine-18-α-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients
Kyoichi Kaira et al.
CHEST (2007)
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003
DG Pfister et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography
D Lardinois et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Preoperative staging of non-small-cell lung cancer with positron-emission tomography.
RM Pieterman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
